RVG29 (YTIWMPENPRPGTPCDIFTNSRGKRASNG), a rabies virus glycoprotein (RVG)-derived peptide containing 29 amino acids, is the most representative ligand peptide for nAchR. RVG29 modification enables nanoparticles to efficiently cross the BBB and recognize neurons, applying to various CNS disorders, such as major depressive disorder (MDD), Alzheimer’s disease (AD), Huntington’s disease (HD), and cerebral ischemia (CI). Since the RVG29 targets the GABA receptor, using genetic engineering, dendritic cells (DCs) have been engineered to secrete exosomes expressing Lamp2, an exosomal membrane protein, fused with the neuron-specific RVG peptide. The RVG peptide-guided exosomes have the potential in cancer therapy.
1. Liu, Y. et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195–4202 (2009).
2. Vadevoo SMP, Gurung S, Lee HS, Gunassekaran GR, Lee SM, Yoon JW, Lee YK, Lee B. Peptides as multifunctional players in cancer therapy. Exp Mol Med. 2023 Jun;55(6):1099-1109. doi: 10.1038/s12276-023-01016-x. Epub 2023 Jun 1.